Leaving Cert applied maths: New topics may have thrown some students
Brendan Williamson, an applied mathematics teacher at the Institute of Education, said that question one, which focused on standard adjacency matrices was a nice, familiar introduction.
'While the mention of 'period of a particle' in part (a) might throw some students, most will have been able to approach the circular motion question,' said Mr Williamson.
'This gentle start is instantly contrasted with a very tricky question two on differential equations. This question deviated from the normal by being both fully on a single topic and requiring students to reproduce a particularly challenging proof.
READ MORE
'Indeed, the later sections of the question contained an oddly subtle shift in how gravity is handled that will put some out. While the nuts and bolts of the mathematics were fine, the overall approach would certainly have deterred many. '
Connected particles
Questions three and five, on connected particles, are often favoured by students looking for relatively easy marks, but the part (b)s in both these questions fell outside the norm, said Mr Williamson.
'Rather than allowing any choice, Q3(b) required students to use Prim's algorithm, and it presented the information in a matrix, which has never happened on the paper before,' he said.
'Question 5 (b) was peculiar in the purity of its mathematics – normally the applied maths exam structures the questions around real world scenarios but this question on abstract vectors was simple and straight to the point.'
There may have been disappointment for students here, he said.
'While students should be aware that not every topic gets examined, the absence of project scheduling, a major part of the course and typically one full question, will have been both jarring and disappointing.
Dynamic programming
Question six was on dynamic programming, a new addition to the course.
'This topic has four elements that can be examined but unfortunately the hardest aspect, equipment replacement and maintenance, appeared,' said Mr Williamson.
'Since this has only been part of the course since 2022, the most effective manner in which teachers and students should approach it is yet to be standardised, so some may really struggle.
'This issue also arose in question 9(a) as the necessary depth of a student's grasp of displacement time graphs and the amount of class time to allocate was not previously clear. Both of these questions will provide helpful insights for teachers in future years but for the current cadre in the exam hall they will be disquieting.'
Projectiles
Question seven, which looked at projectiles that bounce, has not appeared as a topic since 2006 – but the concepts have been a key component of exams for years.
'Since the removal of inclines from the syllabus, students reviewing the relevant past papers will overlook this topic since the two often appeared together,' said Mr Williamson.
'A good teacher would have been sure to reintegrate the bounce calculations back into the course, but a student who was focused on past papers alone will find themselves worried.'
Despite these challenges, Mr Williamson said that there were straightforward options, particularly in question 9(b) and question 10.
'If a student read through all 10 questions before selecting their favourite eight, they will realise that the end of the paper was good enough to offset some of the trickier elements in the middle,' Mr Williamson concluded.
The applied maths exam was scheduled at the same time as the religious education exam, and the Leaving Certificate 2025 is now formally over.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Independent
3 days ago
- Irish Independent
Cork's Fota Wildlife Park hosts free educational family weekends this summer
The three weekends will focus on science, native species and insect life, and take place at the Education, Conservation and Research Centre (ECRC) in Fota. This year's event kicks off this weekend – July 12 and 13 – with the Wild Science Weekend, which features a range of interactive displays, talks and demonstrations designed to make science topics accessible to all ages. Exhibitors include the Tyndall Institute, Irish Bee Conservation Project and The Lifetime Lab @ Old Cork Waterworks, presenting hands-on activities such as MathsWorks and VEX Robotics. Participants will walk through a giant model of the human digestive system, which was created by University College Cork (UCC)'s Alimentary Pharmabiotic Centre. While walking though the digestive system, participants will get a detailed view showcasing how food is transported through the body. Later in July, the Native Species Weekend is the attraction and will focus on Ireland's rich biodiversity with a series of interactive exhibits and biofacts. Fota's education team will be joined by several organisations, including Dublin Zoo, Nature Network Ireland, Irish Bee Conservation Project and Atlantic Technological University (ATU), Galway, among others. Native Species Weekend will take place on July 26 and 27. August will see the return of the Bug Bonanza Weekend, which will take place on August 16 and 17. While the full list of exhibitors is yet to be confirmed, the weekend will focus on invertebrate biodiversity, including talks and displays on insect life both local and exotic. Aileen Tennant, the director of Fota Wildlife Park said the conservation charity, wants to spark curiosity while connecting visitors with science and nature. 'These weekends give families a chance to explore complex ideas in a hands-on, accessible way, with the help of expert partners from across science, academic and conservation fields. 'Fota Wildlife Park protects endangered species through dedicated conservation efforts and educates the public about the importance of biodiversity. 'As a living classroom, through initiatives like these interactive educational weekends, Fota Wildlife Park aims to raise awareness of endangered species, foster a culture of conservation, and inspire every visitor to become a lifelong guardian of the natural world,' she said. The educational weekend events will run from 11am to 4pm each day, and no booking is required as it operates a walk-in only system. All activities are included in the price of entry to Fota Wildlife Park and face painting will also be available, free of charge, from 12pm to 2:45pm on July 12 and 13 at the ECRC. Due to popular demand, the Panoramic Wheel will remain on site at Fota Wildlife Park throughout the summer months. This optional experience is priced from €5 per person and tickets can be purchased separately at the dedicated booth. Fota Wildlife Park is open daily from 9:30am and online booking is available via
Irish Times
4 days ago
- Irish Times
Looming ‘patent cliff' facing Big Pharma adds to sector's woes
Every year, thousands of patients sit in doctors' offices with needles in their arms receiving a dose of a wonder drug called Keytruda. The cancer medicine earned Merck $29.5 billion (€25.2 billion) in sales last year. But drip by drip, the US pharma company's time is running out. In 2028, Keytruda's patent ends, allowing rivals to sell the same drug at a cheaper price. Investors are spooked and Merck's shares have sunk 35 per cent over the past 12 months. While the company has been at pains to show it is prepared, Daina Graybosch, an analyst at Leerink, says the so-called patent cliff is hanging over the business. Merck has a 'massive hole' in its revenue to fill. 'They can't fill it with one drug,' she says. Merck on Wednesday appeared to take a step towards addressing the looming Keytruda patent cliff. The company is closing in on a $10 billion deal to buy London-based biotech Verona Pharma, which has an approved respiratory disease drug that analysts predict could generate peak annual sales of approaching $4 billion. READ MORE Losing the intellectual property rights for blockbuster drugs is a long-standing ritual for pharma companies. Drugmakers can earn fortunes when new discoveries are first sold to patients. Governments grant them about 20 years of patent life per drug. But up to half of that time can be used before the drug gets to market. When the patent is up, competitors are allowed to release generic rivals, potentially wiping out billions of dollars of revenue for the original proprietor. Drugs worth about $180 billion of revenue a year are going off patent in 2027 and 2028, says research firm Evaluate Pharma, representing almost 12 per cent of the global market. Bristol Myers Squibb and Pfizer are also facing 2028 patent expirations for top-selling drugs. The boom-and-bust cycle is the result of an uneasy compromise in how we fund innovation that is expensive to create but cheap to copy. Governments would rather grant limited monopolies to the private sector than fund much of this essential but risky work themselves. Stephen Haber, a professor of political science and history at Stanford University, says that without patents, medicines would not exist. Healthcare systems baulk at expensive new drugs, given to more people as populations age. Developing countries struggle to access the innovation until patents expire. To get through bust periods historically, pharma companies would go on spending sprees, buying up smaller biotechs, where many innovative drugs are discovered, to fill their pipelines in advance of the patent expiry. An uncertain political climate has resulted in the sector at large moving cautiously. First, companies feared that former US president Joe Biden's aggressive Federal Trade Commission could stop deals in their tracks. Then came his successor Donald Trump's threat of US tariffs on the sector. The industry also lacks clarity on how much they will be able to charge for drugs, as politicians pressure them to cut prices. The patent system was established in Britain during the industrial revolution and was first formalised in law in the US. Intellectual property protections were essential to the development of the pharma industry in the late 19th century and to it thriving in countries such as the United States, UK and Germany. 'It's not an accident that there's only a few countries in the world that are huge pharmaceutical developers,' Haber says. When a drug goes off patent, other companies can seek approval for their copycat versions. These are usually made based on reverse engineering and are informed by the proprietor's patent filings. The copycats are then tested to ensure they are equivalent to the branded medicine. But crucially, they do not need to go through the expensive clinical trials process again. The pharma industry suffers from patent cliffs in ways that others such as the tech industry do not. This is mainly because the key active ingredient in a drug is covered by one main patent, which is hard to invent around, and chemical formulas are relatively easy to copy. So pharma companies have to focus relentlessly on refilling their pipelines before their best-sellers lose patent protection. At present, companies actually have plenty of money to spend on deals due to the success of the drugs going off patent plus an industry-wide move to slim down operations. EY estimates that companies are sitting on $1.3 trillion in deal-making firepower. Companies are searching for the 'Goldilocks' targets, neither too big nor too small. In 2009, in advance of the last major patent cliff, there were several megamergers: Pfizer bought Wyeth for $68 billion, Merck bought Schering-Plough for $41 billion and Roche acquired Genentech for $47 billion. But there has not been a megamerger in pharma since 2019, when Bristol Myers Squibb bought Celgene for $90 billion. These huge deals have fallen out of favour with many investors, who worry about competition law scrutiny and see them as tough to integrate. Smaller targets can be relatively cheap as the biotech market is down 50 per cent since its peak in February 2021, and many early-stage companies are trading below cash. But ideally Big Pharma is looking for biotechs with drugs that could come on to the market soon – and sell in their billions. One difference since the last major set of patent cliffs is that companies are now looking for drugs to buy in China . They often buy ex-China rights to early-stage innovative medicines and then conduct the later-stage trials themselves, so they can provide global data to western regulators. So far this year, there have been licensing deals between Chinese companies and US and European partners worth up to $35 billion, data from EY shows. Daniel Parisotto, managing director in healthcare investment banking at Oppenheimer, says Big Pharma is attracted to Chinese assets – typically the rights to develop and sell the drugs outside China – because they have smaller upfront costs than western deals, where much of the price is tied to a drug reaching certain milestones, like trials, or approvals. Drugmakers pay less upfront than they would in the West. 'But ultimately the jury is still out on whether those Chinese assets have a higher failure rate or the same success rate as western assets,' he says. Pharma also deploys strategies to extend the life of its existing drugs. Robin Feldman, a law professor at the University of California San Francisco, says the record for extending a patent beyond the original expiry is more than 30 years. Before Keytruda, the world's bestselling medicine was AbbVie's Humira, a wonder drug that fights arthritis, Crohn's disease and other inflammations. In 2020, AbbVie earned $16 billion in the US alone from Humira, and it was charging $77,000 a year for the drug, a 2021 congressional report said. Humira's basic patent expired in 2016, but AbbVie obtained 132 other patents for administering and making the drug, essentially fortifying Humira's exclusivity with a 'patent thicket'. The last of these patents expires in 2034. US lawmakers baulked at the lingering high cost for Humira and sued AbbVie. The city of Baltimore alleged people were paying millions of dollars unnecessarily to AbbVie and that its patent strategy violated competition law. But in 2022, a US appeals court ruled for the company, saying there was nothing wrong with holding a lot of patents. Nevertheless the pharma industry is facing renewed political scrutiny for such tactics. Trump has railed against high drug prices. In the US, pharma companies have been able to keep rivals off the market by offering discounts to wholesalers and pharmacy benefit managers across a range of drugs in return for not carrying the cheaper rival to the now off-patent branded drug. Despite predictions of a dramatic drop in sales, the 2027-28 cliff could be more like a 'steep hill', says Frank Lichtenberg, professor of healthcare management at Columbia Business School. The blockbuster drugs going off patent are almost all biologics – infusions derived from biological, not chemical, processes – and they are harder to replicate than pills. Lichtenberg thinks it could take five years for sales to slump as much as 75 per cent, far longer than the months it took for some bestselling tablets to be replaced by generics last time. Biosimilars – generic versions of biologics – are harder to reverse engineer and are subject to different laws, which mean branded drugmakers only share broad information about the manufacturing process. When biosimilars get to market, US pharmacists cannot by law automatically swap them in as cheaper alternatives as they can with generics. And when they do, the price drops are not as steep. Lichtenberg estimates they sell for about half the price of the branded drug, rather than 10 or 20 per cent of the price for a generic. The US has been far slower than Europe in adopting biosimilars, but that may soon change. The US Food and Drug Administration (FDA) was already speeding up its process of approving biosimilars and a recent Trump executive order directed the regulator to find ways to accelerate approvals further. The Trump administration is also working on policies that would make it easier for pharmacists to substitute biosimilars for a branded drug as is already done in Europe. For companies such as Merck, all these potential policy changes only add to the uncertainty around how severe their patent cliff will be. It is going to be hard to find another drug that can treat so many patients – or generate so many billions. – Financial Times
Irish Times
07-07-2025
- Irish Times
Disease-carrying ticks are coming for us and they're likely to hang around longer too
The ticks are coming for us. It was only a matter of time. Tick-borne disease risks are on the rise globally, according to the European Commission's environment directorate. Their increase is one of the many ways in which climate change is altering our world. Changes to temperature, rain, and sunlight, particularly in winter, can make a big difference to a tick's ability to thrive. Extra sunlight in January is one of the most influential factors in its ability to flourish. Changes to land use and human-animal interactions are also contributing to why more of these tiny creatures are on the way, says the Chinese research cited by the European Commission this month. READ MORE These researchers have modelled where harmful disease-carrying ticks are likely to thrive in the future as climate changes. [ Ticks, respiratory illnesses, skin cancer and poorer mental health 'all on the rise due to climate change' Opens in new window ] The highest-risk regions for future expanding tick colonisation in Europe include France, Spain, Ukraine, Germany, Italy, Poland, Romania and the UK, according to the research. Indeed, about 50 per cent of land in the UK and 95 per cent of land in Spain offers habitat classed as being of medium-high suitability for ticks, the research says. A rise in disease-carrying ticks will have health implications for all of us. If tick ranges continue to expand, so too will the risk of tick-borne diseases. Ticks feed on the blood of humans, animals and birds. Like some sort of vampire game show, they go through four life stages, each requiring a blood meal from a host to graduate to the next level. Between hosts, ticks can spread some pretty serious diseases - so more of them isn't good news. A bacterial infection called Lyme disease is probably the one most familiar to us in Ireland. About 5 per cent of ticks in Ireland are thought to carry the disease. Up to 400 people a year are estimated to be infected with Lyme disease in Ireland from ticks, according to the HSE . Lyme disease can be hard to diagnose - not everyone spots it when they have been bitten by a tiny tick. The disease is no picnic - if left untreated, symptoms can include tiredness, aches, loss of energy, arthritis, neurological conditions such as facial paralysis and heart problems. Climate change has already extended the peak season for ticks in Ireland, increasing the risk of Lyme disease and other diseases, according to research published by the Irish Medical Journal in 2022. [ How to spot if your child has a tick bite and what to do Opens in new window ] You'll find ticks anywhere in Ireland, including in both urban and rural areas. They are more numerous and active from April to September. 'Anyone who spends time outdoors should protect themselves against tick bites,' Dr Paul McKeown, a public health consultant with the National Health Protection unit has said. Ticks love an arm or leg, but any warm and sweaty parts not covered by clothing will do. In children ticks are most likely to bite around the head and neck. You can limit your risk of a bite by sticking to paths where possible, covering up with long sleeves and long trousers, especially when walking in wooded areas and using insect repellent with DEET, says the HSE. 'Preventing tick bites prevents Lyme disease,' says Dr McKeown. Human behaviour is at the root of climate breakdown. Burning fossil fuels, deforestation, and intensive agriculture are significantly increasing greenhouse gas emissions. The greenhouse effect is trapping more heat and causing global warming. Overconsumption and unsustainable practices are contributing to the problem by increasing demand for energy, goods and resources. We are already seeing the consequences of climate change starting to bite in our lives - more powerful storms are creating damage and knocking out power, heatwaves and wildfires are putting favoured package holiday destinations off limits, there is more flooding, less frost, more water shortages and more erosion. Soon the consequences of climate change may actually be biting us in the form of more ticks.
